Opportunity ID: 335975

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-22-037
Funding Opportunity Title: Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 30, 2021
Last Updated Date: Sep 30, 2021
Original Closing Date for Applications: Feb 04, 2022
Current Closing Date for Applications: Feb 04, 2022
Archive Date: Mar 12, 2022
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Small businesses
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Special district governments
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
City or township governments
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets. Astrocytes are a fundamental component of the neurovascular unit and are known to play a role in regulating the blood brain barrier and APOE signaling. However, the mechanistic role of astrocytes for the neurovascular unit in health and disease, including in vascular contributions to cognitive impairment and dementia (VCID) and across the spectrum of AD/ADRD diagnoses, is largely unknown, and represents a gap area and an opportunity for research investment. This initiative would represent the first targeted initiative on the fundamental role of astrocytes in AD/ADRD at the NIH.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-22-037.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date

Folder 335975 Full Announcement-PAR-22-037 -> PAR-22-037-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or after January 25, 2022 PKG00269847 Jan 04, 2022 Feb 04, 2022 View
FORMS-F Use for due dates on or before January 24, 2022 PKG00269163 Jan 04, 2022 Jan 24, 2022 View

Package 1

Mandatory forms

335975 RR_SF424_5_0-5.0.pdf

335975 PHS398_CoverPageSupplement_5_0-5.0.pdf

335975 RR_OtherProjectInfo_1_4-1.4.pdf

335975 PerformanceSite_4_0-4.0.pdf

335975 RR_KeyPersonExpanded_4_0-4.0.pdf

335975 PHS398_ResearchPlan_4_0-4.0.pdf

335975 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

335975 RR_Budget_3_0-3.0.pdf

335975 RR_SubawardBudget30_3_0-3.0.pdf

335975 PHS398_ModularBudget_1_2-1.2.pdf

335975 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

335975 RR_SF424_2_0-2.0.pdf

335975 PHS398_CoverPageSupplement_5_0-5.0.pdf

335975 RR_OtherProjectInfo_1_4-1.4.pdf

335975 PerformanceSite_2_0-2.0.pdf

335975 RR_KeyPersonExpanded_2_0-2.0.pdf

335975 PHS398_ResearchPlan_4_0-4.0.pdf

335975 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

335975 RR_Budget_1_4-1.4.pdf

335975 RR_SubawardBudget30_1_4-1.4.pdf

335975 PHS398_ModularBudget_1_2-1.2.pdf

335975 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T03:43:43-05:00

Share This Post, Choose Your Platform!

About the Author: